Compare

Cocrystal Pharma, Inc. vs FibroBiologics, Inc. vs Nanoviricides, Inc. vs Can-Fite BioPharma Ltd.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearCocrystal Pharma, Inc.
COCP
FibroBiologics, Inc.
FBLG
Nanoviricides, Inc.
NNVC
Can-Fite BioPharma Ltd.
CANF
Year ended2025-12-312025-12-312026-06-302025-12-31
Revenuen/an/a$0$405.0K
Revenue growth (YoY)n/an/an/a-39.9%
Gross marginn/an/an/an/a
Operating marginn/an/an/an/m
Net marginn/an/an/an/m
Net income-$8.83M-$18.65M-$8.22M-$9.83M
EPS (Diluted)-$0.78-$0.42-$0.41-$5.97
Operating cash flow-$8.19M-$16.39M-$7.70M-$8.95M
Free cash flow-$8.20M-$16.66M-$7.78M-$8.95M
Cash & equivalents$7.03M$4.89M$2.79M$5.53M
Total assets$9.71M$9.62M$9.87M$9.51M
Total liabilities$3.38M$3.46M$1.20Mn/a
Shareholders' equity$6.33M$6.16M$8.68M$5.59M
Return on year-end equity-139.5%-302.9%-94.7%-175.8%
Shares outstanding13.78Mn/a23.01M2.62M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearCocrystal Pharma, Inc.FibroBiologics, Inc.Nanoviricides, Inc.Can-Fite BioPharma Ltd.
Latest$2.01M
Ended 2020-12-31
n/a$0
Ended 2026-06-30
$405.0K
Ended 2025-12-31
1 year earlier$6.56M
Ended 2019-12-31
n/a$0
Ended 2025-06-30
$674.0K
Ended 2024-12-31
2 years earliern/an/a$0
Ended 2024-06-30
$743.0K
Ended 2023-12-31
3 years earliern/an/a$0
Ended 2023-06-30
$810.0K
Ended 2022-12-31
4 years earliern/an/an/a$853.0K
Ended 2021-12-31